XML 79 R67.htm IDEA: XBRL DOCUMENT v3.23.2
Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Segment Reporting Information [Line Items]        
Total revenues $ 21,323 $ 38,406 $ 34,305 $ 73,746
Cost of product revenue 3,178 11,270 7,698 19,791
Research and development 17,334 19,089 33,988 38,590
Selling, general and administrative 13,365 10,656 28,765 26,360
Restructuring charges 72 0 145 0
Total costs and operating expenses 33,949 41,015 70,596 84,741
Loss from operations (12,626) (2,609) (36,291) (10,995)
Unallocated depreciation and amortization (1,480) (1,341) (2,946) (2,556)
Stock-based compensation 2,716 3,231 5,525 7,069
Product revenue        
Segment Reporting Information [Line Items]        
Total revenues 11,048 34,645 19,412 65,335
Research and development revenue        
Segment Reporting Information [Line Items]        
Total revenues 10,275 3,761 14,893 8,411
Operating segments        
Segment Reporting Information [Line Items]        
Total revenues 21,323 38,406 34,305 73,746
Cost of product revenue 3,178 11,270 7,698 19,791
Research and development 16,096 18,007 31,507 36,475
Selling, general and administrative 2,223 4,556 5,972 8,816
Restructuring charges 72 0 145 0
Total costs and operating expenses 21,569 33,833 45,322 65,082
Loss from operations (246) 4,573 (11,017) 8,664
Stock-based compensation 2,716 3,231 5,525 7,069
Operating segments | Performance Enzymes        
Segment Reporting Information [Line Items]        
Total revenues 19,308 36,530 28,794 69,629
Cost of product revenue 3,178 11,270 7,698 19,791
Research and development 7,856 6,929 15,955 13,051
Selling, general and administrative 2,032 3,876 4,830 7,416
Restructuring charges 0 0 0 0
Total costs and operating expenses 13,066 22,075 28,483 40,258
Loss from operations 6,242 14,455 311 29,371
Stock-based compensation 924 1,493 1,959 3,183
Operating segments | Novel Biotherapeutics        
Segment Reporting Information [Line Items]        
Total revenues 2,015 1,876 5,511 4,117
Cost of product revenue 0 0 0 0
Research and development 8,240 11,078 15,552 23,424
Selling, general and administrative 191 680 1,142 1,400
Restructuring charges 72 0 145 0
Total costs and operating expenses 8,503 11,758 16,839 24,824
Loss from operations (6,488) (9,882) (11,328) (20,707)
Stock-based compensation (80) 358 333 768
Operating segments | Product revenue        
Segment Reporting Information [Line Items]        
Total revenues 11,048 34,645 19,412 65,335
Operating segments | Product revenue | Performance Enzymes        
Segment Reporting Information [Line Items]        
Total revenues 11,048 34,645 19,412 65,335
Operating segments | Product revenue | Novel Biotherapeutics        
Segment Reporting Information [Line Items]        
Total revenues 0 0 0 0
Operating segments | Research and development revenue        
Segment Reporting Information [Line Items]        
Total revenues 10,275 3,761 14,893 8,411
Operating segments | Research and development revenue | Performance Enzymes        
Segment Reporting Information [Line Items]        
Total revenues 8,260 1,885 9,382 4,294
Operating segments | Research and development revenue | Novel Biotherapeutics        
Segment Reporting Information [Line Items]        
Total revenues 2,015 1,876 5,511 4,117
Corporate, non-segment        
Segment Reporting Information [Line Items]        
Total costs and operating expenses (9,788) (5,789) (20,152) (16,994)
Unallocated depreciation and amortization (1,480) (1,316) (2,946) (2,549)
Loss before income taxes (11,514) (2,532) (34,115) (10,879)
Stock-based compensation $ 1,872 $ 1,380 $ 3,233 $ 3,118